The performance of docetaxel-loaded solid lipid nanoparticles targeted to hepatocellular carcinoma
文献类型：期刊论文
| 作者 | Xu, Zhenghong; Chen, Lingli ; Gu, Wangwen; Gao, Yu; Lin, Liping; Zhang, Zhiwen; Xi, Yong; Li, Yaping
|
| 刊名 | BIOMATERIALS
 |
| 出版日期 | 2009-01 |
| 卷号 | 30期号:2页码:226-232 |
| 关键词 | Chemotherapy Cytotoxicity Hepatocellular carcinoma Nanoparticles Docetaxel |
| ISSN号 | 0142-9612 |
| DOI | 10.1016/j.biomaterials.2008.09.014 |
| 文献子类 | Article |
| 英文摘要 | Human hepatocellular carcinoma (HCC) is one of the major causes of death worldwide. Targeted uptake of therapeutic agent in the cell-, tissue- or disease-specific manner represents a potential technology for the treatment of HCC. A new docetaxel-loaded hepatoma-targeted solid lipid nanoparticle (tSLN) was designed and prepared with galactosylated dioleoylphosphatidyl ethanolamine. The cellular cytotoxicity, cellular uptake, subcellular localization, in vivo toxicity, therapeutic effect, biodistribution and histology of tSLNs were investigated, The tSLNs showed the particle size about 120 nM with encapsulation efficiency > 90%, a low burst effect within the first day and a sustained release for the next 29 days in vitro. Cytotoxicity of tSLNs against hepatocellular carcinoma cell line BEL7402 was superior to Taxotere (R) and non-targeted SLNs (nSLNs). The tSLNs also showed better tolerant and antitumor efficacy in murine model bearing hepatoma compared with Taxotere (R) or nSLNs. The studies on cellular uptake and biodistribution indicated that the better antitumor efficacy of tSLNs was attributed to both the increased accumulation of drug in tumor and more cellular uptake by hepatoma cells. The histology demonstrated that tSLNs had no detrimental effect on both healthy liver and liver with fibrosis. These results implied that this targeted nanocarrier of docetaxel could enhance its antitumor effect in vivo with low systemic toxicity for the treatment of locally advanced and metastatic HCC. (c) 2008 Elsevier Ltd. All rights reserved. |
| WOS关键词 | PHASE-II ; GALACTOSYLATED LIPOSOMES ; ANTICANCER DRUGS ; HEPATOMA-CELLS ; CHEMOTHERAPY ; PACLITAXEL ; CANCER ; RECEPTOR ; PHARMACOKINETICS ; FORMULATION |
| 资助项目 | The National Basic Research Program of China[2007CB935804] ; The National Basic Research Program of China[2006CB933304] ; National Natural Science Foundation of China[30572259] ; CAS[KJCX2.YW.M02] ; CAS[KSCX1-YW-R-21] |
| WOS研究方向 | Engineering ; Materials Science |
| 语种 | 英语 |
| WOS记录号 | WOS:000261272100011 |
| 出版者 | ELSEVIER SCI LTD |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/279350]  |
| 专题 | 药物制剂研究中心 |
| 通讯作者 | Li, Yaping |
| 作者单位 | Chinese Acad Sci, Shanghai Inst Mat Med, Shanghai 201203, Peoples R China |
| 推荐引用方式 GB/T 7714 | Xu, Zhenghong,Chen, Lingli,Gu, Wangwen,et al. The performance of docetaxel-loaded solid lipid nanoparticles targeted to hepatocellular carcinoma[J]. BIOMATERIALS,2009,30(2):226-232. |
| APA | Xu, Zhenghong.,Chen, Lingli.,Gu, Wangwen.,Gao, Yu.,Lin, Liping.,...&Li, Yaping.(2009).The performance of docetaxel-loaded solid lipid nanoparticles targeted to hepatocellular carcinoma.BIOMATERIALS,30(2),226-232. |
| MLA | Xu, Zhenghong,et al."The performance of docetaxel-loaded solid lipid nanoparticles targeted to hepatocellular carcinoma".BIOMATERIALS 30.2(2009):226-232. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。